C4 Therapeutics, Inc.
C4 Therapeutics is an early stage a drug discovery company whose mission is to harness targeted protein degradation to develop therapeutics for a broad range of diseases. The centerpiece of our approach is the Degronimid® platform, which enables highly selective small molecule binders to target disease causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system